Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMT-002 in T1D Patients with HLA-DQ8
NCT04625595Phase 1Completed
- Sponsor
- IM Therapeutics
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of D-methyldopa in type 1 diabetes mellitus (T1D) (5 arms), sponsored by IM Therapeutics. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) at Day 21, Change from baseline in electrocardiogram (ECG) at Day 21 and 1 more. Started Nov 2020; status: completed.
02
Drugs
D-methyldopa
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04625595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625595.